Stock Events

Stock Events

Petros Pharmaceuticals 

$0.002000
50
+$0.00+0%Friday 19:09

Statistics

Day High
0.0024
Day Low
0.002
52W High
0.024
52W Low
0.002
Volume
64,100
Avg. Volume
134,134
Mkt Cap
84,746
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Dec 2Expected
Q3 2024
Q4 2024
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-8.25
-5.51
-2.77
-0.03
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-50.1MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PTPI. It's not an investment recommendation.
Plug Power
4
PLUG
Fuelcell Energy
4
FCEL
Ocugen
4
OCGN
Tesla
3
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap158.45B
Pfizer is a global pharmaceutical company that competes with Petros Pharmaceuticals in the development and marketing of medications for various conditions, including those in men's health, which is a focus area for Petros.
Lilly(Eli) &
LLY
Mkt Cap1.02T
Eli Lilly is a competitor because it offers a range of pharmaceutical products that address conditions similar to those targeted by Petros Pharmaceuticals, including erectile dysfunction.
Merck
MRK
Mkt Cap356.01B
Merck & Co. competes in the pharmaceutical sector by providing innovative health solutions and medications that could overlap with Petros Pharmaceuticals' market, especially in men's health.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap46.1B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing with Petros Pharmaceuticals in areas like urological health.
Abbvie
ABBV
Mkt Cap464.43B
AbbVie, having acquired Allergan, competes with Petros Pharmaceuticals through its diverse portfolio that includes men's health and urology.
GSK
GSK
Mkt Cap94.23B
GlaxoSmithKline competes in various therapeutic areas, including those relevant to Petros Pharmaceuticals' focus, such as urology and men's health.
Astrazeneca
AZN
Mkt Cap243.34B
AstraZeneca is involved in the discovery and development of prescription medicines that could compete with Petros Pharmaceuticals, particularly in the broader healthcare market.
Johnson & Johnson
JNJ
Mkt Cap617.01B
Johnson & Johnson, through its pharmaceutical segment, competes across a broad range of healthcare areas, including those targeted by Petros Pharmaceuticals.

About

Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.
Show More
CEO
Fady Boctor
Employees
3
Country
United States
ISIN
US71678J3086

Listings

OTC Link
US
PTPI

0 Comments

Share your thoughts

FAQs

What is Petros Pharmaceuticals stock price today?▼
The current price of PTPI is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Petros Pharmaceuticals stock price performance more closely on the chart.
What is Petros Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Petros Pharmaceuticals stocks are traded under the ticker PTPI.
Is Petros Pharmaceuticals stock price growing?▼
PTPI stock has risen by +0% compared to the previous week, the month change is a -46.67% fall, over the last year Petros Pharmaceuticals has showed a -89.47% decrease.
What is Petros Pharmaceuticals market cap?▼
Today Petros Pharmaceuticals has the market capitalization of 84,746
When is the next Petros Pharmaceuticals earnings date?▼
Petros Pharmaceuticals is going to release the next earnings report on December 2, 2026.
What is Petros Pharmaceuticals revenue for the last year?▼
Petros Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Petros Pharmaceuticals net income for the last year?▼
PTPI net income for the last year is -50.1M USD.
How many employees does Petros Pharmaceuticals have?▼
As of November 2, 2026, the company has 3 employees.
In which sector is Petros Pharmaceuticals located?▼
Petros Pharmaceuticals operates in the Health & Wellness sector.
When did Petros Pharmaceuticals complete a stock split?▼
The last stock split for Petros Pharmaceuticals was on May 1, 2025 with a ratio of 1:25.
Where is Petros Pharmaceuticals headquartered?▼
Petros Pharmaceuticals is headquartered in New York City, United States.